ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims

Key Takeaways

• FDA issued warning letter to ImmunityBio regarding claims made by executives about lead immunotherapy drug Anktiva
• Securities class action lawsuit filed covering investors who purchased IBRX stock between January 19-March 24, 2026
• Legal action targets statements made by Chairman Dr. Patrick Soon-Shiong about the company’s biologic product portfolio

---

SAN FRANCISCO - ImmunityBio, Inc. (NASDAQ: IBRX) is facing mounting regulatory and legal pressure following an FDA warning letter and subsequent securities class action lawsuit that could significantly impact the biotechnology company’s market position.

FDA Warning Letter Triggers Legal Action

The controversy centers on claims made by ImmunityBio’s executive chairman and Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, regarding the company’s lead biologic product Anktiva. The FDA’s warning letter, issued in early 2026, questioned statements about the IL-15 superagonist immunotherapy that has been approved for cancer treatment.

Hagens Berman, the law firm representing investors, announced the class action lawsuit on April 23, 2026, seeking to represent shareholders who purchased ImmunityBio securities during the critical period from January 19 through March 24, 2026.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for oncology/immunotherapy, with Anktiva most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Investor Concerns

The dual regulatory and legal challenges represent a significant setback for ImmunityBio, which operates in the highly competitive immunotherapy market alongside major pharmaceutical companies like Bristol Myers Squibb, Merck, and Roche. The company’s stock price volatility during the class period suggests substantial investor losses, prompting the securities litigation.

Dr. Soon-Shiong, a prominent figure in biotechnology and the company’s key spokesperson, has been central to ImmunityBio’s public communications about Anktiva’s potential. The FDA’s scrutiny of his statements raises questions about regulatory compliance and corporate governance practices.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Compliance Under Scrutiny

The FDA warning letter highlights ongoing concerns about how biotechnology companies communicate about their approved products. For ImmunityBio, which has invested heavily in developing its immunotherapy platform for cancer patients, the regulatory action could impact future product development and marketing strategies.

Anktiva, as an IL-15 superagonist, represents a significant investment in the company’s oncology portfolio. The drug’s mechanism of action involves stimulating the immune system to fight cancer cells, positioning it within a large and growing market for cancer immunotherapies.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology/immunotherapy pricing, access, and launch sequencing.

Legal Timeline and Next Steps

Investors who experienced substantial losses during the class period have the opportunity to serve as lead plaintiffs in the lawsuit. The legal action will likely focus on whether ImmunityBio’s executives made materially misleading statements about Anktiva’s capabilities or market prospects.

The outcome of both the FDA’s regulatory review and the securities litigation could have lasting implications for ImmunityBio’s reputation and market valuation. While the underlying drug platform may remain scientifically viable, the company faces the challenge of rebuilding investor confidence while addressing regulatory compliance concerns.

IntelligenceStrategic Takeaways▾

FDA issued warning letter to ImmunityBio regarding claims made by executives about lead immunotherapy drug Anktiva Securities class action lawsuit filed covering investors who purchased IBRX stock between January 19-March 24, 2026 Legal action targets statements made by Chairman Dr. Patrick Soon-Shiong about the company’s biologic product portfolio

Industry Implications

This case underscores the critical importance of accurate corporate communications in the biotechnology sector, where investor decisions often rely heavily on executive statements about drug development and regulatory prospects. The involvement of high-profile leadership in allegedly problematic claims adds reputational risk beyond the immediate legal and regulatory challenges.

---

Frequently Asked Questions

What does the FDA warning letter mean for Anktiva patients?

The FDA warning letter addresses executive claims rather than drug safety, so current Anktiva patients should continue their prescribed treatment and consult their healthcare providers about any concerns.

How will this lawsuit affect ImmunityBio’s stock price?

The lawsuit and FDA warning letter have already contributed to stock volatility. Future price movements will depend on legal resolution, regulatory compliance, and investor confidence restoration.

What makes this case different from other biotech legal challenges?

This case involves both regulatory scrutiny of executive statements and securities litigation, with a prominent industry figure (Dr. Soon-Shiong) at the center of the controversy, creating both compliance and reputational risks.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• ANKTIVA

Related coverage

• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx